Back to Journals » Nutrition and Dietary Supplements » Volume 3

Subchronic toxicity (90 days) of StemEnhance™ in Wistar rats

Authors Dirikolu L, Chakkath T, Ball-Kell S, Elamma C, Schaeffer DJ

Published 15 February 2011 Volume 2011:3 Pages 19—30

DOI https://doi.org/10.2147/NDS.S16503

Review by Single-blind

Peer reviewer comments 3


Levent Dirikolu1, Thushara Chakkath1, Susan Ball-Kell2, Christy Elamma2, David J Schaeffer1
1Department of Comparative Biosciences, 2Veterinary Diagnostic Laboratory, College of Veterinary Medicine, University of Illinois at Urbana-Champaign, Urbana, IL, USA

Abstract: This study evaluated the subchronic toxicity of StemEnhance™, an extract of the blue-green alga Aphanizomenon flos-aquae that is used as a health supplement. Groups of 12 rats of each sex were given either 5% glycerin in water (control) or 200 mg/kg of StemEnhance prepared in 5% glycerin in water for 90 days by oral gavage. The administration of StemEnhance had no effect on behavior, food and water intake, growth, or survival. Values at the end of dosing and observation periods did not reveal differences between treated and control groups for hematology and clinical chemistry. There were no significant differences in the gross and histopathology of the reproductive organs in either males or females. Sperm motility parameters were similar for control and treated males. Our results show that StemEnhance at doses ~7 times the maximum label-recommended daily dose did not produce adverse effects in Wistar rats after subchronic treatment.

Keywords: algal toxicology, blue-green algae, cyanobacteria, Aphanizomenon flos-aquae

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]